CytomX Therapeutics (NASDAQ:CTMX) expects to raise $100 million in its upcoming IPO. Based in South San Francisco, California, CytomX Therapeutics is a biopharmaceutical company focused on developing treatments for cancer.

CTMX will offer 6.67 million shares at an expected price range of $14 to $16. If the underwriters price the IPO at the midpoint of that range, CTMX will have a market capitalization of $524 million. CTMX filed for the IPO on August 28, 2015.

Lead Underwriters: BofA Merrill Lynch, Cowen & Co., and Jefferies LLC

Underwriters: Oppenheimer & Co.

Business Summary

CytomX Therapeutics is a biopharmaceutical company that focuses on developing treatments for cancer. It has created a novel class of antibody therapeutics based upon its Probody technology platform, which addresses clinically validated cancer targets, such as PD-L1, in addition to novel targets CD-166.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the U.S. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166.

CytomX Therapeutics has the following drug candidates in development PD-L1 (CX-072), CD-166 PDC, PD-1, CD-71 PDC, ITGA3 PDC, T-cell Engaging Biospecifics, Cancer Immuno-therapies (in collaboration with Bristol-Myers Squibb (NYSE:BMS), PDCs (in collaboration with Pfizer, and PDCs (in collaboration with ImmunoGen).

See CytomX’s pipeline here.

The Probody technology platform creates a therapeutic antibody that remains in active until it reaches the targeted tumor. Their therapies are expected to have greater efficacy and better safety profiles than other cancer treatments due to the capacity to target specific tumors while leaving surrounding health tissue untouched.

In its SEC filing, the company notes that cancer is the second leading cause of death in the U.S., accounting for close to 25 percent of all deaths annually. Current research into cancer treatments has evolved from small molecule chemotherapy agents to cancer immunotherapies that support and trigger the body’s own immune system to attack tumors.